Despite a slowdown in deal making, pharmaceuticals and healthtech continue to get attention from investors.
The current economic climate opens the door for investors and innovators to rethink partnerships and ways to access capital.
The FED is experiencing criticism for being too slow to tighten financial conditions, and failing to recognize inflation. Executives from Mercer discuss the potential recession and whether it will it cause a significant impact.
Health systems are seeking payment increases to shore up finances that have been hit hard by COVID-19 and rising labor costs. We identified key considerations for insurers as they enter these negotiations.
Healthcare organizations need to think about their partnerships — whether with private equity or other types of entities — through a strategic lens.
Maximize Value
January 06, 2022
Big Pharma Turning Into Focused Pharma
Pharmaceutical giants are shedding business units with an eye toward focusing on their innovative pharma operations and targeted therapeutic areas.
Insurance markets showed great resiliency during the past 18 months as employment numbers fluctuated. Looking ahead, multiple legislative, regulatory, and market moves may cause shifts in the payer enrollment mix.
Maximize Value
September 08, 2021
Lowering Healthcare Costs and the Number of Uninsured
Impact of Extending the American Rescue Plan Act Premium Tax Credits Beyond 2022
Oliver Wyman analysis —conducted for the White House—highlights how the ARPA will make health insurance more affordable for millions of Americans.
Maximize Value
June 24, 2021
Price Transparency Predictions
Out-of-Industry Lessons for Healthcare Leaders
Healthcare leaders have much to learn from the retail and aviation industries in their journey to transparency.
We're entering the Great Unknown regarding health insurance enrollment mix.